TY - JOUR
T1 - Impact of older age at Fontan completion on mid-term survival
AU - Aurora, Ruth Grace
AU - Prakoso, Radityo
AU - Fakhri, Dicky
AU - Sakidjan, Indriwanto
AU - Siagian, Sisca Natalia
AU - Almazini, Prima
AU - Lilyasari, Oktavia
N1 - Funding Information:
The authors would like to thank Renan Sukmawan, MD, PhD, Head of the Department of Cardiology and Vascular Medicine, Universitas Indonesia.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: The optimum age of Fontan completion remains unknown. Currently, the majority of centers worldwide are performing Fontan completion at 2–4 years of age. In Indonesia, lack of awareness and limited resources probably explain why patients seek treatment at advanced stage. This study aimed to evaluate the impact of older age at Fontan completion on mid-term survival. Results: A single-center retrospective cohort study was performed on 261 patients who underwent Fontan completion between 2008 and 2019 and survived to discharge. The patients were followed up until April 2020, with a median follow-up period of 3 years (range 0–12 years). The median age was 5 years (range 2–24 years). The survival rates of patients with the age at operation ≤ 6 years and > 6 years were 92.1% and 82.8%, respectively. A subgroup analysis showed that the survival rates for age < 4 years, 4–6 years (reference age), 6–8 years, 8–10 years, 10–18 years, and > 18 years were 85.7%, 94.8%, 85.4%, 78.8%, 85.7%, and 66.7%, respectively. Age at Fontan completion of > 6 years (HR 3.84; p = 0.020) was associated with a lower 12-year survival rate. The age at operation of 8–10 years (HR 6.79; p = 0.022) and > 18 years (HR 15.30; p = 0.006) had the worst survival rates. Conclusions: An older age at Fontan completion (> 6 years) significantly reduced mid-term survival rate. The age at Fontan of 8–10 years and > 18 years had higher risk of mid-term death than age of 4–6 years.
AB - Background: The optimum age of Fontan completion remains unknown. Currently, the majority of centers worldwide are performing Fontan completion at 2–4 years of age. In Indonesia, lack of awareness and limited resources probably explain why patients seek treatment at advanced stage. This study aimed to evaluate the impact of older age at Fontan completion on mid-term survival. Results: A single-center retrospective cohort study was performed on 261 patients who underwent Fontan completion between 2008 and 2019 and survived to discharge. The patients were followed up until April 2020, with a median follow-up period of 3 years (range 0–12 years). The median age was 5 years (range 2–24 years). The survival rates of patients with the age at operation ≤ 6 years and > 6 years were 92.1% and 82.8%, respectively. A subgroup analysis showed that the survival rates for age < 4 years, 4–6 years (reference age), 6–8 years, 8–10 years, 10–18 years, and > 18 years were 85.7%, 94.8%, 85.4%, 78.8%, 85.7%, and 66.7%, respectively. Age at Fontan completion of > 6 years (HR 3.84; p = 0.020) was associated with a lower 12-year survival rate. The age at operation of 8–10 years (HR 6.79; p = 0.022) and > 18 years (HR 15.30; p = 0.006) had the worst survival rates. Conclusions: An older age at Fontan completion (> 6 years) significantly reduced mid-term survival rate. The age at Fontan of 8–10 years and > 18 years had higher risk of mid-term death than age of 4–6 years.
KW - Age at operation
KW - Fontan completion
KW - Mid-term survival
KW - Older age
UR - http://www.scopus.com/inward/record.url?scp=85139840729&partnerID=8YFLogxK
U2 - 10.1186/s43044-022-00314-5
DO - 10.1186/s43044-022-00314-5
M3 - Article
AN - SCOPUS:85139840729
SN - 1110-2608
VL - 74
JO - Egyptian Heart Journal
JF - Egyptian Heart Journal
IS - 1
M1 - 75
ER -